FinscoFinsco

Abbott Laboratories (US.ABT)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ABT · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion76.4%↑
ROE3.9%↓
Cash Conversion189.7%↑
D/E Ratio0.64↓
Gross Margin57.0%→
US.ABT (Abbott Laboratories) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    76.4%    ↑
ROE                3.9%    ↓
Cash Conversion  189.7%    ↑
D/E Ratio          0.64    ↓
Gross Margin      57.0%    →
Key Metrics
US.ABT (Abbott Laboratories) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 76.4% ↑
ROE 3.9% ↓
Cash Conversion 189.7% ↑
D/E Ratio 0.64 ↓
Gross Margin 57.0% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies